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ABSTRACT 
Background: Chronic kidney disease (CKD) is highly prevalent in atrial fibrillation (AF) patients and 
associated with an increased risk of adverse outcomes. Our objectives were to study clinical 
features associated with CKD in AF patients and the impact of CKD on anticoagulation control, as 
reflected by time in therapeutic range (TTR). We also determined the impact of CKD and TTR in 
predicting adverse outcomes. 
Methods and Results: We analysed pooled datasets from SPORTIF III and V trials, including 3,646 
patients assigned to warfarin with data on renal function.  CKD (creatinine clearance <60 ml/min) 
was present in 952 (26%) patients.  TTR was higher in patients with normal renal function 
compared to those with CKD (p<0.001).  
On logistic analysis, chronic AF and male sex were associated with TTR>70%, whilst diabetes 
mellitus, aspirin use and CKD were inversely associated with TTR>70%. On Cox regression analysis, 
CKD was an independent predictor for stroke (p=0.006) and death (p<0.001). TTR>70% was 
independently associated with a lower risk of stroke (p=0.024), death (p=0.001) and major 
bleeding (p=0.001). 
Conclusions: CKD is highly prevalent among AF patients and a risk factor for stroke and death. 
Adjusting for CKD, good quality anticoagulation control (TTR>70%) was an independent predictor 
for lower risks of stroke, death and major bleeding.  
 
Keywords: non-valvular atrial fibrillation; chronic kidney disease; stroke; major bleeding; clinical 
outcomes. 
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Chronic kidney disease (CKD) is highly prevalent in non-valvular AF patients, ranging from 26% to 
32%, especially in the elderly (Apostolakis et al., 2013; Banerjee et al., 2013). The presence of CKD 
in AF patients is associated with a greater risk of adverse clinical outcomes, including stroke, 
thromboembolism and bleeding.  In the Danish nationwide cohort study, for example, the 
presence of CKD amongst patients with AF was significantly associated with an increased risk for 
stroke/systemic embolism  (by 1.49-fold), all-cause mortality (by 2.37-fold), myocardial infarction 
(by 2-fold) and major bleeding (by 1.33-fold)(Olesen et al., 2012).  Warfarin use amongst such 
patients has been associated with a substantial risk reduction in overall event rates, with a positive 
net clinical benefit(Bonde et al., 2014). Similarly, the Loire Valley Atrial Fibrillation Project 
confirmed the high risk associated with CKD in patients with AF(Banerjee et al., 2014, 2013). In 
clinical trial populations, CKD also confers a much higher relative risk for both stroke and 
bleeding(Apostolakis et al., 2013; Piccini et al., 2013).  
 
When Vitamin K Antagonists (VKAs, e.g. warfarin) are used for thromboprophylaxis, good quality 
anticoagulation control, as reflected by time in therapeutic range (TTR) >70% is recommended (De 
Caterina et al., 2013). Limited information been reported on the relationship between CKD and 
TTR in AF patients, but good TTR has been associated with lower risks of thromboembolism and 
bleeding (Connolly et al., 2008; Friberg et al., 2014; Pokorney et al., 2015). 
 
In this study, our objectives were to study clinical features associated with CKD in AF patients; 
second, we studied the impact of CKD on anticoagulation control, as reflected by the time in 
therapeutic range (TTR).  Third, we determined the impact of CKD as a risk factor for stroke, 
myocardial infarction, major bleeding and death amongst warfarin-treated AF patients, after 
adjustment for TTR as measure of anticoagulation control. 
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METHODS 
 
For the present analysis, we used the pooled study populations of the Stroke Prevention using an 
Oral Thrombin Inhibitor in patients with atrial Fibrillation (SPORTIF) III and V trials. The original 
protocol and principal results have been previously described(Albers et al., 2005; Halperin, 2003; 
Olsson, 2003).  In brief, the SPORTIF trials were two multicentre phase III clinical trials comparing 
the efficacy and safety of the direct thrombin inhibitor, ximelagatran, against warfarin in patients 
with non-valvular AF.  SPORTIF III was an open label trial, while SPORTIF V was a double blind 
study(Halperin, 2003).  Signed, informed consent was required from each participant in 
accordance with protocol regulations approved by the local review boards governing research 
involving human subjects, and the Declaration of Helsinki.  In both SPORTIF trials, ximelagatran 
was non-inferior in efficacy and safety as warfarin for stroke prevention in non-valvular AF 
patients (Lip, 2005) but due to hepatotoxicity, ximelagatran was withdrawn.  For the purpose of 
this study, we studied only SPORTIF patients assigned to warfarin treatment where complete 
information on renal function was available. 
 
Thromboembolic Risk and Anticoagulation Control 
Thromboembolic risk was categorised according to both CHADS2 and CHA2DS2-VASc scores (Gage 
et al., 2004; Lip et al., 2010). Based on CHADS2, patients were categorised as “low risk” when with 
CHADS2=0, “moderate risk” with CHADS2=1 and “high risk” when CHADS2≥2 (Gage et al., 2004).  
Based on the CHA2DS2-VASc score, “low risk” was defined as a CHA2DS2-VASc 0 in males or 1 in 
females; “moderate risk” as male patients with CHA2DS2-VASc=1; and “high risk” with CHA2DS2-
VASc ≥2 (Camm et al., 2012; Lip et al., 2015). 
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Anticoagulation control, as reflected by the TTR was calculated using the standardized Rosendaal 
interpolation method(Rosendaal et al., 1993), by assigning an INR value to each day between two 
successive observed INR values. The percentage of time that the interpolated INR remained 
between 2.0 and 3.0 was used to establish TTR value, and the cut-off value for defining optimal 
anticoagulation was a mean individual TTR of ≥70%(De Caterina et al., 2013). 
 
Renal Function 
Renal function was based on the estimated creatinine clearance (CrCl), using the 4-item Cockroft-
Gault formula [ (140-age)*(weight in kg)*(0.85 if female) / (72*creatinine) ]. Accordingly, an 
estimated CrCl level of less than 60 ml/min was used to define CKD, based on established 
guidelines (“K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, 
classification, and stratification.,” 2002). 
 
Study Outcomes 
Principal clinical outcomes were based on the original study protocol, and were centrally 
adjudicated(Halperin, 2003).  Stroke was defined as the acute onset of a focal neurological deficit 
in any of the carotid, vertebral or cerebral artery distribution territories lasting >24 hours.  As per 
the SPORTIF trials protocol, myocardial infarction (MI) diagnosis required 2 out of 3 of the 
following criteria: (i) typical chest pain lasting at least 20 minutes; (ii) electrocardiographic changes 
clearly indicating an acute MI; (iii) significant, i.e. >2x upper limit, elevation of cardiac biomarkers 
(creatine kinase-MB, troponin).  Based on the International Society of Thrombosis and 
Haemostasis (ISTH) criteria(Schulman and Kearon, 2005), major bleeding was defined by one of 
the following: clinically overt bleeding with a concomitant fall in haemoglobin levels more than 2 
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g/dl or requiring blood transfusion of at least 2 units of whole blood or erythrocytes; bleeding 
episode involving a critical site. 
 
Statistical Analysis 
All continuous variables were tested for normality with the Shapiro-Wilk test. Variables with 
normal distribution were expressed as means and standard deviations (SD), and tested for 
differences using a t-test. Non-parametric variables were expressed as median and interquartile 
range (IQR) and differences tested using the Mann-Whitney U test. Categorical variables, 
expressed as counts and percentages, were analysed by chi-squared test. A linear regression 
analysis between CrCl and TTR was performed, adjusted for type of AF and thromboembolic risk.   
 
Regression analysis was performed in order to establish clinical factors significantly associated 
with the presence of CKD. All variables different between the two groups at the baseline with a 
level of significance of at least p<0.10 underwent a univariate analysis, and those predictors with a 
level significance of p<0.10 were inserted into a forward multivariate logistic model. To determine 
the factors associated with a TTR>70%, both for general population and CKD-only population, all 
baseline clinical variables underwent univariate analyses and those predictors with a level 
significance of p<0.10 were inserted into a forward multivariate logistic model. In order to explore 
the incremental value of TTR in determining events occurrence, a correlation analysis between 
TTR and hazard risk for study outcomes was performed using Pearson product-moment 
correlation test, both for the overall cohort and stratified according to CKD presence. Correlation 
coefficients were then compared using the z test, after being processed with Fisher 
transformation. 
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Survival analysis, assessed by an intention-to-treat approach, was performed according to the 
presence of CKD and differences in survival distributors between subgroups were analysed using 
the Log-Rank test. Evaluation of the clinical characteristics significantly associated with outcomes 
was performed using a Cox proportional hazards analysis, corrected according to thromboembolic 
risk, performed with CKD both as a categorical variable and CrCl as a continuous variable. All 
demographic variables, comorbidities and risk factors analysed at baseline underwent a univariate 
analysis.  All variables with a p-value <0.10 for the association with clinical outcome at the 
univariate analysis, were inserted into the forward stepwise multivariate model. A backward 
model was then performed to verify the results of the forward one. A two-sided p value <0.05 was 
considered statistically significant. All analyses were performed using SPSS v. 22.0 (IBM, NY, USA) 
and R v. 3.2.1 (The R Foundation). 
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RESULTS 
 
The pooled study population constituted 7,329 patients, of which 3,665 were assigned to the 
warfarin treatment arm.  Complete data on renal function were available for 3,646 (99.5%) [Figure 
1]. Of the selected cohort, 30.5% (n=1,113) were female, median age was 72 [IQR 66-77] years, 
and median CrCl was 78.60 [59.1-102.1] ml/min.  Of the entire cohort, 10.8% (n=393) had 
paroxysmal AF. 
 
Prevalence of CKD and Associated Clinical Characteristics  
CKD (defined as CrCl<60 ml/min) was present in 952 (26.1%) patients. Clinical characteristics of 
patients with and without CKD are shown in Table 1.  Patients with CKD were significantly older 
(p<0.001), more commonly female (p<0.001) or paroxysmal AF (p=0.009) and a lower median 
weight (p<0.001). CKD patients had more prevalent coronary heart disease (CHD) (p=0.042) and 
previous stroke or transient ischemic attack (TIA) (p<0.001).  Thromboembolic risk was higher in 
patients with CKD compared to those with normal renal function, whether based on CHADS2 
(median [IQR] 2 [2-2] vs. 2 [1-2] respectively, p<0.001) and CHA2DS2-VASc (median [IQR] 4 [3-5] vs. 
3 [2-3], p<0.001).   
 
On multivariable logistic regression analysis, clinical characteristics significantly associated with 
the presence of CKD were age (Odds Ratio (OR) 1.16 per year, 95% confidence interval (CI) 1.15-
1.18, p<0.001), weight (OR for any kg 0.92, 95% CI 0.91-0.92, p<0.001), paroxysmal AF (OR 1.67, 
95% CI 1.23-2.27, p=0.001), diabetes mellitus (OR 1.47, 95% CI 1.16-1.86, p=0.001), chronic heart 
failure (CHF) (OR 1.61, 95% CI 1.32-1.96, p<0.001), and previous stroke/TIA (OR 1.41, 95% CI 1.13-
1.75, p=0.002). 
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Relationship between CKD and TTR 
Median TTR in the whole cohort was 68.6% [IQR 56.5-80.6%], being significantly higher in patients 
with normal renal function when compared with CKD patients (p<0.001).  Also, the proportion 
with TTR>70% was more prevalent in patients with normal renal function (p<0.001).   
 
After adjustment for type of AF and thromboembolic risk, a linear relationship was found between 
CrCl and TTR (standardized beta: 0.054, p=0.003) [Figure 2]. On multivariable logistic analysis, the 
presence of chronic AF (OR 1.56, 95% CI 1.25-1.94, p<0.001) and male sex (OR 1.18, 95% CI 1.01-
1.35, p=0.033) were positively associated with a TTR>70%.  Conversely, a previous diagnosis of 
diabetes mellitus (OR 0.82, 95% CI 0.70-0.96, p=0.011), concomitant use of aspirin (OR 0.75, 95% 
CI 0.63-0.88, p<0.001) and the presence of CKD (OR 0.75, 95% CI 0.67-0.92, p=0.002) were 
negatively associated with achieving a TTR>70%.   
 
In the CKD subgroup (n=952), the weight (OR per kg 1.01, 95% CI 1.00-1.02, p=0.041), the 
presence of CHF (OR 1.38, 95% CI 1.05-1.81, p=0.022) and chronic AF (OR 1.85, 95% CI 1.22-2.81, 
p=0.004) were significantly associated with TTR>70%. 
 
Impact of CKD in Predicting Adverse Clinical Outcomes  
After a median [IQR] follow-up time of 1.6 [1.3-1.8] years, 504 events (13.8% of patients) were 
recorded, as follows: 90 strokes (17.9% of total events), 52 myocardial infarctions (10.3%), 198 
deaths (39.3%) and 164 major bleeding events (32.5%). 
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(a) Stroke 
Stroke was more common in CKD patients than in patients with normal renal function (2.6% 
patient-years vs. 1.3% patient-years, respectively), with the unadjusted hazard ratio (HR) for 
stroke being 1.99 (95% CI: 1.30-3.03, p=0.001). With CrCl as a continuous variable, every decrease 
of 10 ml/min was associated with a higher risk of stroke [HR 1.07, 95% CI 1.00-1.14, p=0.048).  
 
On Kaplan-Meier analysis, CKD patients had a higher risk of stroke compared to patients with 
normal renal function (Log-Rank test: 10.56; p=0.001) [Figure 3, Panel A]. On multivariable Cox 
regression analysis, a clinical history of CHD (p=0.045), a previous stroke/TIA (p<0.001) and the 
presence of CKD (p=0.006) were independent risk factors associated with the occurrence of 
stroke, while TTR>70% (p=0.004) was inversely associated with the risk of stroke (Table 2).  Cox 
regression analysis performed using CrCl as a continuous variable (Table 2) shows that its influence 
in determining stroke risk became non-significant, after adjusting for other clinical risk factors 
(p=0.337).  A backward selection model also confirmed these results. TTR and HR for occurrence of 
stroke were inversely correlated (r= -0.772, p<0.001). Similarly, there was a significant correlation 
between TTRs and stroke HRs according to renal function subgroups [Figure 4, Panel A] (r= -0.569, 
p<0.001). A significant difference when comparing the two correlation coefficients for the overall 
cohort and stratified according to CKD presence, respectively (z=8.61, p<0.001). 
 
(b) Myocardial Infarction: 
The crude incidence rate of MI was similar between those with CKD and normal renal function 
(1.1% and 0.9% patient-years, respectively). No significant association was found between CKD 
and MI (unadjusted HR 1.19, 95% CI 0.66-2.18, p=0.563).   
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(c) Major Bleeding: 
Major bleeding was more common in patients with CKD than in those with normal renal function 
(4.6% patient-years, vs. 2.8% patient-years, respectively). Similar to stroke, patients with CKD had 
a significantly higher risk of a major bleeding event, compared to those with normal renal function 
(Log-Rank: 10.03; p=0.002) [Figure 3, Panel B].  
 
CKD conferred a higher risk of major bleeding (unadjusted HR 1.67, 95% CI 1.21-2.31, p=0.002). 
This risk was non-significant when CrCl was considered as a continuous variable (per decrease of 
10 ml/min, HR 1.04, 95% CI 0.99-1.09, p=0.093). On multivariable analysis (see Table 2), increasing 
age (p=0.009) and clinical history of CHF (p=0.036) were risk factors for major bleeding; 
conversely, TTR>70% (p=0.007) was independently associated with less major bleeding. Entering 
CrCl in the analysis as a continuous variable did not affect the multivariable model (Table 2). 
Similar data were obtained when performing a backward selection model. 
 
When correlating TTR and HR for major bleeding, a significant inverse relationship was found in 
the overall cohort (r= -0.527, p<0.001). When performed with HR according to renal function 
subgroups [Figure 4, Panel B], there was a numerical reduction in correlation coefficient (r= -0.490, 
p<0.001), but this was non-significant (z=1.57, p=0.116). 
 
(d) All-cause Death: 
A higher rate of death was found in patients with CKD compared to those with normal renal 
function (crude incidence rate 6.4% patient-years vs. 2.5% patient-years; unadjusted HR 2.54 (95% 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 12 
CI 1.92-3.36, p<0.001)). As for stroke, a decrease of 10 ml/min in CrCl was found associated with a 
higher risk of death (HR 1.14, 95% CI 1.08-1.20, p<0.001).  
 
Survival analysis confirmed a higher mortality of patients with CKD compared to patients with 
normal renal function (Log-Rank test: 45.62; p<0.001) [Figure 3, Panel C]. Multivariable Cox 
regression analysis (Table 2) shows that female sex (p=0.013) and TTR>70% (p=0.002) were 
independently associated with a lower risk of death; conversely, a clinical history of CHF (p=0.004), 
CHD (p<0.001), smoking habit (p=0.049) and the presence of CKD (p<0.001) were risk factors 
associated with an increased risk of death. When the Cox multivariable analysis was performed 
using CrCl as a continuous variable, a decrease of 10 ml/min was associated with a higher risk of 
death (Table 2). No difference was found when backward selection model was performed. 
 
Similar to stroke, there was significant inverse correlation between unadjusted HR for death and 
TTR (r= -0.676, p<0.001), but the correlation coefficient was reduced (r= -0.478, p<0.001) when 
stratifying according to CKD presence [Figure 4, Panel C]. The difference between correlation 
coefficients was significant (z=8.40, p<0.001)]. 
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DISCUSSION 
 
In this study, we demonstrate that more than a quarter of AF patients have CKD, and that age, 
female sex, CHF, previous stroke/TIA and the occurrence of paroxysmal AF were significantly 
associated with CKD in AF patients. Second, we found a linear association between CrCl and TTR in 
AF, and those patients with CKD had poorer anticoagulation control, as shown by a lower TTR 
when compared to patients with normal renal function. Importantly, the presence of CKD was 
negatively associated with achieving a TTR>70%.  Third, CKD was an independent risk factor for 
the occurrence of stroke and death, independently from TTR; however, no significant association 
was found between CKD and both myocardial infarction or major bleeding after adjusting for TTR.  
Conversely, adequate anticoagulation control as expressed by TTR>70% was inversely associated 
with major bleeding.    
 
Clinical factors associated with CKD have been previously reported in a smaller real-world’ 
populations of AF patients and our data are broadly confirmatory of the role of age, diabetes 
mellitus and CHF in predicting the presence of CKD in AF patients(Roldán et al., 2013).  Indeed, 
both increasing age and diabetes mellitus are major predictors of CKD in the general 
population(Fox, 2004). Conversely, hypertension (an important risk factor for CKD in general 
population(Fox, 2004)) had no significant influence on CKD among AF patients in our trial cohort. 
 
CKD is predictive of stroke in AF patients, whilst oral anticoagulation with VKA lowers stroke risk 
albeit at a higher risk of bleeding(Hart et al., 2011). The Loire Valley Atrial Fibrillation Project 
showed that CKD, defined as an estimated glomerular filtration rate (eGFR) below 60 ml/min/1.73 
m2, was associated with a higher incidence of ischemic stroke/thromboembolism events, but 
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multivariable Cox regression analysis did not demonstrate an independent effect of renal 
impairment on predicting major adverse events, after adjusting for CHA2DS2-VASc score risk 
factors(Banerjee et al., 2014, 2013). 
 
Our results demonstrate that even in AF patients treated with warfarin, CKD was still associated 
with a higher incidence of stroke, independent of other concomitant risk factors. These data 
support previous findings from another prospective randomised trial, where the presence of a CrCl 
<60 ml/min was associated with two-fold higher risk of stroke compared with those with CrCl≥ 60 
ml/min(Apostolakis et al., 2013). Importantly, we show that the predictive ability of CKD in 
identifying patients with a greater risk of stroke was independent of anticoagulation control, as 
reflected by the TTR, notwithstanding the latter being a strong predictor of adverse outcomes in 
patients with AF(White et al., 2007).   
 
The lack of significant association between CrCl when analysed as a continuous variable, and the 
risk of stroke could be attributed to more complex and multifactorial physiological alterations 
present in patients with established CKD that statistical adjustments would not be able to fully 
adjust for.  Indeed, the risk of cardiovascular disease is non-linear in the transition from one 
functional CKD class to another, but increases exponentially with greater impairment of renal 
function(Schiffrin et al., 2007). 
 
Our study also supports previous evidence showing that CKD is associated with a higher risk for 
major bleeding(Apostolakis et al., 2013; Banerjee et al., 2014), even when stratified according to 
VKA treatment(Banerjee et al., 2014). Nonetheless, major bleeding is strongly related to the 
quality of anticoagulation control, and supra-therapeutic INR values amongst CKD patients are 
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associated with a higher risk of developing a major bleed especially with progressive renal 
impairment(Limdi et al., 2015).  In contrast to other previous studies(Olesen et al., 2012), we failed 
to show a significant association with MI risk, but given the low number of MIs recorded, this lack 
of association could partially be due to an inadequate sample size, and being unpowered. Finally, 
we found that CKD was an independent predictor for a higher risk of all cause death, consistent 
with prior studies (Apostolakis et al., 2013; Banerjee et al., 2014; Olesen et al., 2012). Importantly, 
the high risk for death in our study was independently related to CKD and inversely to effective 
anticoagulation (TTR>70%).   
 
Our data strengthen and reinforce the relationship between renal function and TTR(Kleinow et al., 
2011; Kooiman et al., 2014).  One study derived from a cohort of anticoagulated AF patients found 
that patients with moderate and severe CKD had higher TTR than patients with normal renal 
function, although CKD patients spent more time above therapeutic range and INR-variability 
significantly increased in patients with moderate and severe CKD(Kooiman et al., 2014).  Recently, 
an analysis from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation 
(ORBIT-AF) registry found that an estimated glomerular filtration rate below 60 ml/min/1.73 m2 
was significantly associated with a reduced TTR (≤53%) (Pokorney et al., 2015). Our results 
strongly reinforce this relationship between renal function and anticoagulation control, and that 
CKD patients derived benefit from VKA treatment with good TTRs(Bonde et al., 2014). 
 
Good quality anticoagulation control (TTR>70%) was an independent predictor for a lower risk of 
stroke, death and major bleeding.  There was a significant inverse correlation between TTR and HR 
risk function for stroke, death and major bleeding overall, but when this analysis was repeated in 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 16 
the CKD subgroup, the degree of correlation was reduced for stroke and death risk, perhaps 
reflecting how CKD modulates the risk of adverse events. 
 
Limitations 
Renal function data was only available based on the Cockroft-Gault formula and not by more 
recent and validated methods of eGFR evaluation(Levey et al., 2015).  The original trial protocol 
excluded patients with a severe CKD, and this may have led to an underestimate in the prevalence 
of CKD in AF population. Also, the absence of subjects with severe CKD precluded a more detailed 
analysis of the wider spectrum of renal function and its influence on TTR and clinical outcomes.  
Moreover, other parameters used to evaluate anticoagulation control (e.g. time spent below or 
above the target, proportion of INRs in range, etc.) were not available for this analysis.  Since the 
original trials were run between 2000 and 2002, current clinical practice in managing AF patients 
could have changed, with possible implications for the generalizability of our results. However, 
VKAs are still very widely used worldwide for thromboprophylaxis, in particular for treating AF 
patients with CKD(Potpara et al., 2015). Thus, the association between CKD and TTR remains 
relevant during the decision-making process to prescribe the right drug for the right patient 
(Shields and Lip, 2015). Finally, the association of CKD with paroxysmal AF could be spurious, since 
only a low proportion of these subjects were enrolled in the original trial cohort. 
 
In conclusion, CKD is highly prevalent among AF patients and associated with several clinical 
comorbidities.  Importantly, CKD in AF patients is an independent risk factor for stroke and death, 
but not major bleeding after adjustment for TTR.  Even after adjusting for CKD, good quality 
anticoagulation control (TTR>70%) was an independent predictor for a lower risk of stroke, death 
and major bleeding.
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 17 
 
HIGHLIGHTS 
 Chronic kidney disease (CKD) in atrial fibrillation (AF) patients is associated with several clinical 
factors; 
 There is a linear association between creatinine clearance and time in therapeutic range (TTR); 
 CKD is a risk factor for stroke and death, while TTR>70% is a predictor for stroke, major 
bleeding and death. 
 
RESEARCH IN CONTEXT 
The concomitant presence of atrial fibrillation (AF) and chronic kidney disease (CKD) confers an 
increased risk of both ithromboembolism and bleeding. Oral anticoagulation with vitamin K 
antagonist (VKA) are an effective treatment in preventing thromboembolic events, but good 
anticoagulation control as reflected by a high time in therapeutic range (TTR) is crucial in reducing 
thromboembolic and bleeding adverse events.  Our results showed a close relationship between 
CKD, TTR and adverse events. In the decision-making process of prescribing VKA, clinicians need to 
consider renal function as well as good anticoagulation control (eg. TTR>70%) to ensure best 
efficacy and safety.    
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TABLE 1: Patient Characteristics in Relation to Baseline Renal Function 
 
N (%) 
Normal Renal 
Function 
(≥60 ml/min) 
N=2,694 
Chronic Kidney 
Disease 
(<60 ml/min) 
N=952 
p 
Age, years (median [IQR]) 70 [64-75] 78 [74-82] <0.001 
Weight, kg (median [IQR]) 89 [78-100] 70 [61-79] <0.001 
Female 656 (24.4) 457 (48.0) <0.001 
Creatinine Clearance, ml/min 88.86 [74.02-111.57] 49.77 [43.01-55.25] <0.001 
Type of Atrial Fibrillation (n= 3,644) 
Paroxysmal 
Chronic 
 
269 (10.0) 
2,424 (90.0) 
 
124 (13.0) 
827 (87.0) 
0.009 
Heart Rate (n= 3,510), per min 76 [67-87] 73 [64-86] <0.001 
Hypertension 2,082 (77.3) 717 (75.3) 0.216 
Diabetes Mellitus 652 (24.2) 205 (21.5) 0.095 
Current Smoker 272 (10.1) 58 (6.1) <0.001 
Coronary Heart Disease 1,162 (43.2) 447 (46.9) 0.042 
Chronic Heart Failure 988 (36.7) 378 (39.7) 0.097 
Previous Stroke/TIA 485 (18.0) 263 (27.6) <0.001 
Previous Bleeding 154 (5.7) 54 (5.7) 0.958 
Aspirin Use 518 (19.2) 205 (21.6) 0.119 
TTR (n= 3,606), % (median [IQR]) 69.6 [56.7-80.2] 66.6 [51.9-76.8] <0.001 
TTR>70% (n= 3,606) 1,307 (48.9) 390 (41.8) <0.001 
Median [IQR] CHADS2 2 [1-2] 2 [2-2] <0.001 
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CHADS2 score    
0 99 (3.7) 13 (1.4)  
1 1,233 (45.8) 196 (20.6) <0.001 
≥2 1,362 (50.6) 743 (78.0)  
Median [IQR] CHA2DS2-VASc 3 [2-3] 4 [3-5] <0.001 
CHA2DS2-VASC risk class   <0.001 
Low Risk 8 (0.3) 1 (0.1)  
Intermediate Risk 457 (17.0) 19 (2.0)  
High Risk 2,229 (82.7) 932 (97.9)  
Legend: BPM= Beats per Minute; IQR= Interquartile Range; TIA= Transient Ischemic Attack; TTR= 
Time in Therapeutic Range. *Low Risk= Male patients with CHA2DS2-VASC 0 or Female patients 
with CHA2DS2-VASC 1; Intermediate Risk= Male Patients with CHA2DS2-VASC 1; High Risk= All 
Patients with CHA2DS2-VASC ≥2.   
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TABLE 2: Multivariable Cox Regression Analysis for Clinical Outcomes performed with Chronic 
Kidney Disease as a Categorical Variable or Creatinine Clearance as a Continuous Variable 
 Multivariable Analysis 
 Hazard Ratio 95% CI p 
Categorical Variable    
STROKE    
TTR>70% 0.63 0.41-0.98 0.040 
Coronary Heart Disease 1.54 1.01-2.34 0.042 
Chronic Kidney Disease* 1.82 1.19-2.80 0.006 
Previous Stroke/TIA 2.23 1.44-3.44 <0.001 
MAJOR BLEEDING    
TTR>70% 0.58 0.42-0.80 0.001 
Age (per year) 1.03 1.01-1.05 0.009 
Chronic Heart Failure  1.40 1.02-1.92 0.036 
DEATH    
TTR>70% 0.63 0.47-0.84 0.002 
Female 0.66 0.47-0.92 0.013 
Chronic Heart Failure 1.53 1.14-2.04 0.003 
Current Smoker 1.54 1.00-2.38 0.049 
Coronary Heart Disease 1.77 1.32-2.37 <0.001 
Chronic Kidney Disease* 2.58 1.92-3.46 <0.001 
Continuous Variable    
STROKE    
TTR>70% 0.60 0.39-0.93 0.024 
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Coronary Heart Disease 1.54 1.01-2.34 0.045 
Previous Stroke/TIA 2.18 1.40-3.38 0.001 
MAJOR BLEEDING    
TTR>70% 0.58 0.42-0.80 0.001 
Age (per year) 1.03 1.01-1.05 0.009 
Chronic Heart Failure  1.40 1.02-1.92 0.036 
DEATH    
TTR>70% 0.61 0.46-0.82 0.001 
Female 0.69 0.49-0.96 0.029 
Current Smoker 1.55 1.00-2.38 0.047 
Chronic Heart Failure 1.58 1.19-2.12 0.002 
Coronary Heart Disease 1.75 1.30-2.35 <0.001 
Creatinine Clearance (per 10 ml/min decrease) 1.13 1.07-1.19 <0.001 
Legend: CI= Confidence Interval; TIA= Transient Ischemic Attack; TTR= Time in Therapeutic Range. 
*Creatinine Clearance <60 ml/min.  
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FIGURE LEGENDS 
 
FIGURE 1: Patients Included in this Analysis 
 
FIGURE 2: Scatterplot and Regression Line between Creatinine Clearance and TTR 
LEGEND= TTR: time in therapeutic range. 
 
FIGURE 3: Cumulative Event-Free Survival in Patients According to the Presence of Chronic 
Kidney Disease.  
Panel A) Stroke p=0.001; Panel B) Major Bleeding p=0.002; Panel C) Death p<0.001. 
LEGEND= Solid Line: Normal Renal Function; Dashed Line: CKD. 
 
FIGURE 4: Correlation Between TTR and Hazard Risk According to Presence of Chronic Kidney 
Disease.  
Panel A) Stroke p<0.001; Panel B) Major Bleeding p<0.001; Panel C) Death p<0.001. 
LEGEND= Cross and Solid Line: Normal Renal Function; Square and Dashed Line: CKD. 
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